These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 16574455)
1. Hyponatraemia associated with lopinavir--ritonavir? Roberts MT; Aliyu SH Int J Infect Dis; 2007 Jan; 11(1):83-4. PubMed ID: 16574455 [No Abstract] [Full Text] [Related]
2. [From HAART to "smart": maximizing the advantages of lopinavir/ritonavir]. MMW Fortschr Med; 2004 Apr; 146 Spec No 1():68-9. PubMed ID: 15373055 [No Abstract] [Full Text] [Related]
3. Hair loss in an HIV-1 infected woman receiving lopinavir plus ritonavir therapy as first line HAART. Bongiovanni M; Chiesa E; Monforte Ad; Bini T Dermatol Online J; 2003 Dec; 9(5):28. PubMed ID: 14996401 [No Abstract] [Full Text] [Related]
4. Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children. Larrú B; Resino S; Bellón JM; de José MI; Fortuny C; Navarro ML; Gurbindo MD; Ramos JT; Soler Palacín P; Léon JA; Asensi M; Mellado MJ; Muñoz-Fernández MA J Antimicrob Chemother; 2008 Jan; 61(1):183-90. PubMed ID: 18025025 [TBL] [Abstract][Full Text] [Related]
8. Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency. Resino S; Bellón JM; Muñoz-Fernández MA; J Antimicrob Chemother; 2006 Mar; 57(3):579-82. PubMed ID: 16446377 [No Abstract] [Full Text] [Related]
9. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen. Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990 [TBL] [Abstract][Full Text] [Related]
10. Lopinavir + ritonavir tablets: new formulation. More convenient, but minimal evaluation. Prescrire Int; 2007 Aug; 16(90):148. PubMed ID: 17724839 [TBL] [Abstract][Full Text] [Related]
11. [Overcoming weaknesses in therapy. Protease inhibitors with high IQ]. MMW Fortschr Med; 2001 Apr; 143 Suppl 1():96-7. PubMed ID: 11373795 [No Abstract] [Full Text] [Related]
14. [No resistance even after 1 year. New drug combination against HIV]. MMW Fortschr Med; 2001 Apr; 143 Suppl 1():108. PubMed ID: 11373766 [No Abstract] [Full Text] [Related]
15. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. van Vonderen MG; Lips P; van Agtmael MA; Hassink EA; Brinkman K; Geerlings SE; Sutinen J; Ristola M; Danner SA; Reiss P AIDS; 2009 Jul; 23(11):1367-76. PubMed ID: 19424051 [TBL] [Abstract][Full Text] [Related]
16. Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir. Martínez E; Domingo P; Galindo MJ; Milinkovic A; Arroyo JA; Baldovi F; Larrousse M; León A; de Lazzari E; Gatell JM Clin Infect Dis; 2004 Apr; 38(7):1017-23. PubMed ID: 15034836 [TBL] [Abstract][Full Text] [Related]
17. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy. Staszewski S; Babacan E; Stephan C; Haberl A; Carlebach A; Gute P; Klauke S; Hermschulte Y; Stuermer M; Dauer B; J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902 [TBL] [Abstract][Full Text] [Related]
18. Recurrent oedema associated with the co-formulation of lopinavir and ritonavir. Pinto JF; Eyer-Silva WA; Morais-de-Sá CA Rev Soc Bras Med Trop; 2004; 37(4):357-8. PubMed ID: 15334273 [No Abstract] [Full Text] [Related]